Search Results

Visiongain has published a new report entitled Alzheimer’s Therapeutics 2022-2032.

Psoriasis therapeutic market estimated to reach $11.4B in 2020

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it has completed enrollment of approximately 50% of the 525 patients planned for its Phase III ACRobat™ trial to evaluate its drug candidate Piclidenoson as a first-line treatment for rheumatoid arthritis (RA).

Marken today announced it will open a third branch in Germany in the first quarter of 2018 to meet new demands in the region.

Study initiation will prompt a milestone payment from the recently signed deal with Gebro Holding

Can-Fite BioPharma Ltd. announced the publication of a paper entitled “Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson” in the Journal of Immunology Research, a peer-reviewed, online open access journal.